Disease · MONDO_0043544
nosocomial infection
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. nosocomial infection. Diseases, record MONDO_0043544. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043544
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Healthcare-associated infection, hospital-acquired infection, hospital-onset infection, nosocomial infectious disease
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 22 drugs, from EMA Human Drugs, at withdrawal
- Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DORIPENEM | CHEMBL491571 | Small molecule | Approval | EMA Human Drugs, at withdrawal | 1 | 0 | 0 | Drugs and targets |
| TELAVANCIN | CHEMBL507870 | Protein | Approval | EMA Human Drugs, at withdrawal | 1 | 0 | 0 | Drugs and targets |
| ALANYL GLUTAMINE | CHEMBL3707366 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEFOTAXIME | CHEMBL1730 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEFTRIAXONE | CHEMBL161 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CIPROFLOXACIN | CHEMBL8 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| COLISTIN | CHEMBL6067481 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| NYSTATIN | CHEMBL5465559 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TOBRAMYCIN | CHEMBL1747 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOLGRAMOSTIM | CHEMBL2109134 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 2 | Mu opioid receptor agonist; Mu opioid receptor partial agonist | Unknown | https://conductscience.org/library/genes/4988 | Drugs and targets |
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1438 | Drugs and targets |
| CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1439 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 1 | Granulocyte colony stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 1 | Kappa opioid receptor partial agonist | Unknown | https://conductscience.org/library/genes/4986 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00248638 | Efficacy and Mechanisms of GLN Dipeptide in the SICU | Phase 3 | 150 | 2014-02-13 | Critical Illness | ALANYL GLUTAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT02326467 | Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age | Phase 1 | 10 | 2021-07-27 | Chlorhexidine Allergy, Infection, Rash | CHLORHEXIDINE GLUCONATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02389036 | Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients | Phase 3 | 20,010 | Critical Illness, Sepsis, Septic Shock, Ventilator Associated Pneumonia | CEFOTAXIME, CEFTRIAXONE, CIPROFLOXACIN, COLISTIN, NYSTATIN, TOBRAMYCIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT06818565 | Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. | Not applicable | 150 | Acute-On-Chronic Liver Failure | AVIBACTAM, CEFTAZIDIME, MEROPENEM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07085624 | Early Optimization of Ceftazidime Regimen in Critical Care | Not applicable | 128 | Infection in ICU, Sepsis, Septic Shock, Pseudomonas Aeruginosa Infection | CEFTAZIDIME | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00435305 | Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion | 40 | Pneumonia, Bacteremia | LINEZOLID, MEROPENEM, PIPERACILLIN, TAZOBACTAM, VANCOMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05201560 | Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation | Not applicable | 40 | Analgesia, Hospital-acquired Infections | BUTORPHANOL TARTRATE, FENTANYL | Its record names the disease | ClinicalTrials.gov | |
| NCT05042271 | PK of Meropenem in Patients on Plasma Exchange | 15 | Autoimmune Diseases | MEROPENEM | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Glutamine Dipeptide vs Standard: Hospital Mortality Rate | 11 of 75 | 13 of 75 | 150 | NCT00248638 | Trial comparisons |
| Glutamine Dipeptide vs Standard: deaths from any cause | 11 of 75 | 13 of 75 | 150 | NCT00248638 | Trial comparisons |
| Glutamine Dipeptide vs Standard: serious adverse events | 39 of 75 | 40 of 75 | 150 | NCT00248638 | Trial comparisons |
Papers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0043544
GET https://conductscience.org/api/diseases/v1/MONDO_0043544/drugs?page=2